@ProfManchanda

Prof Wolfson Institute of Population Health, QMUL; Consultant Gynae-Oncologist Barts Health NHS Trust; Hon Prof LSHTM; Precision Prevention in Women’s Cancers

 London, UK
bartscancer.london/staff/professor-ranjit-manchanda/
Joined November 2019
  • Tweets861
  • Following480
  • Followers1.1K
75Media
Prof Ranjit Manchanda retweeted
Ovarian Cancer Research Alliance
@ocrahopeAug 31
Hear expert perspectives on prevention and early detection from invited speakers Barbara Norquist, MD, of University of Washington, and Ranjit Manchanda, MD, MRCOG, PhD, of Queen Mary University of London. Learn from them and other ovarian cancer researchers at the 16th Biennial Rivkin Ovarian Cancer Research Symposium, Oct. 16-18, 2026. The Symposium also fosters networking and collaboration through poster sessions, breakout discussions, and career development opportunities. Register today: bit.ly/4qFXznc @BarbNorquist @ProfManchanda @LondonU @QMUL @UW
At the top of the graphic is the following logo: "OCRA 16th BIENNIAL RIVKIN OVARIAN CANCER RESEARCH SYMPOSIUM. October 16 - 18, 2026. Philadelphia, PA." Underneath are images of Barbara Norquist, MD, and Ranjit Manchanda, MD, MRCOG, PhD. Text at bottom of graphic reads: "Prevention & Early Detection: Barbara Norquist, MD, and Ranjit Manchanda, MD, MRCOG, PhD."

ALT At the top of the graphic is the following logo: "OCRA 16th BIENNIAL RIVKIN OVARIAN CANCER RESEARCH SYMPOSIUM. October 16 - 18, 2026. Philadelphia, PA." Underneath are images of Barbara Norquist, MD, and Ranjit Manchanda, MD, MRCOG, PhD. Text at bottom of graphic reads: "Prevention & Early Detection: Barbara Norquist, MD, and Ranjit Manchanda, MD, MRCOG, PhD."

2
2
186
Prof Ranjit Manchanda retweeted
ESGO
@ESGO_societySep 3
Which workshop will you choose? 🤓 Register early for #ESGO2027 in London 🇬🇧 to: 🔸 claim a spot at your favourite workshop 🔸 secure free childcare 🔸 access the early registration discounts! #gynonc
2
4
387
Prof Ranjit Manchanda retweeted
Ane Gerda Z Eriksson MD PhD@agz_erikssonAug 7
🇳🇴Kick off the fall in Oslo! 🗓️September 10th-11th 🏆First-come-first-serve 🆓No registration fee Join our #GynOncology meeting with @ESGO_society, @Oslounivsykehus & @TeamEndo_MSK @TeamOvary_MSK speakers! ✅Tumorboard ✅Lectures ✅Debates ✅Interactive discussions
1
6
10
655
Health-related quality of life after risk-reducing #hysterectomy (PRESCORES): a cross-sectional study Health-related quality-of-life in women with #LynchSyndrome is likely to be lower following RRH in younger, pre-menopausal women thelancet.com/journals/eclin…
3
7
319
Prof Ranjit Manchanda retweeted
OncoDaily
@oncodailyAug 2
PRESCORES Study Examines Quality of Life After Preventive Hysterectomy for Lynch Syndrome - Ranjit Manchanda @ProfManchanda oncodaily.com/insight/ranjit…
1
3
208
thelancet.com/journals/eclin… Delighted to see our PRESCORES paper put in Eclinicalmedicine @eClinicalMed Risk Reducing Hysterectomy has a QOL detriment in premenopausal but not post menopausal women with Lynch Syndrome Significant reduction in cancer worry overall

Health-related quality of life after risk-reducing hysterectomy (PRESCORES): a cross-sectional study

Health-related quality-of-life in women with Lynch Syndrome is likely to be lower following RRH in younger, pre-menopausal women. This is relevant for counselling, RRH decision making, and economic...

thelancet.com
1
3
11
438
1120 Pt with LS. 25 NHS trusts. Thx to all participants, PIs, stakeholders, collaborators and @LynchSyndromeUK @eveappeal @OvarianCancerUK @Ovacome @athenalamnisos1 @MCPlatt @kevinjmonahan @neilajryan @wpp_wiph @QMUL_WIPH @peachestrust @ESGO_society @QMUL_CCSPED @LynchCancers
1
5
83
@EHTG_Tweets @tsmith1571 @QMUL
2
35
A population-based digital study offering people testing for cancer genes, to identify people at increased risk of cancer so they can take steps to prevent it or detect it early. The PROTECT-C Study registered at #ISRCTN by @ProfManchanda isrctn.com/ISRCTN17289436 #clinicaltrials
PROTECT-C is a research study offering genetic testing to identify people with inherited changes that increase the risk of breast, ovarian, bowel, or womb cancer, regardless of personal or family history. These cancers make up half of all cancers in women, and a proportion are linked to cancer genes that can be managed through NHS screening or preventive options. Current NHS testing criteria miss many people with genetic changes, meaning most remain unaware of their risk. The study will offer testing to 5000 people for nine cancer genes and provide personalised breast and ovarian cancer risk estimates using the CANRISK algorithm. It will assess how many people choose testing, how many genetic changes are found, how many would be missed by standard criteria, and how women respond to personalised risk information. The study will also evaluate user experiences, decision making, uptake of screening or prevention, and NHS affordability.

ALT PROTECT-C is a research study offering genetic testing to identify people with inherited changes that increase the risk of breast, ovarian, bowel, or womb cancer, regardless of personal or family history. These cancers make up half of all cancers in women, and a proportion are linked to cancer genes that can be managed through NHS screening or preventive options. Current NHS testing criteria miss many people with genetic changes, meaning most remain unaware of their risk. The study will offer testing to 5000 people for nine cancer genes and provide personalised breast and ovarian cancer risk estimates using the CANRISK algorithm. It will assess how many people choose testing, how many genetic changes are found, how many would be missed by standard criteria, and how women respond to personalised risk information. The study will also evaluate user experiences, decision making, uptake of screening or prevention, and NHS affordability.

1
1
2
6
1,006
eur01.safelinks.protection.o… Good to see the coverage of the NHS JBRCA programme in the JC, highlighting its importance, outreach and benefit. Thx to the huge number of community and professional stakeholders who have supported it. thx to NHSE for the continued support.

EXCLUSIVE: NHS will restart life-saving ‘Jewish cancer gene’ tests - The Jewish Chronicle

Programme testing for BRCA mutation to resume next year after successful launch results, Health Secretary tells JC

thejc.com
2
2
5
168
more replies
@QMUL @QMBCI @QMUL_WIPH @wpp_wiph @eveappeal @OvarianCancerUK @TargetOvarian @Ovacome @BreastCancerNow @PreventBC
1
1
1
111
@
74
Prof Ranjit Manchanda retweeted
Women's Precision Prevention@wpp_wiph15 Dec 2025
A great time was had by the #WPP_team at our 2025 Christmas party! There have been many wonderful achievement this year; with PhDs, clinical fellowships, Grants, publications and much more to celebrate! Many thanks to Ranjit Manchanda and to Vic White for organising the party.
1
2
94
Good to see our paper finally out Important implications for guidelines and clinical practice This can shorten the diagnostic pathway @eveappeal @BAGPGynPath @BGCS_org @EngageEsgo @ESGO_society @Ovacome @TargetOvarian @OvarianCancerUK @ENYGO_official @ovarcome @IGCSociety
Women's Precision Prevention@wpp_wiph15 Dec 2025
Our paper ‘Consent model for tumour genetic testing in ovarian cancer’ shows strong support for reflex tumour genetic testing. Most patients, physicians, and charity representatives favoured testing without explicit consent, alongside an opt-out option. tandfonline.com/doi/full/10.…
1
3
4
609
@QMUL @QMBCI @QMUL_WIPH @wpp_wiph
82
Well done Priyanka Onwards and upwards
Women's Precision Prevention@wpp_wiph15 Dec 2025
Congratulations to our WPP member Priyanka Deshmukh on being awarded PPI grant of £966 from the QMUL Centre for Public Engagement. This PPI work will help inform the design of a future project ‘LEGACY – Lynch Evaluation for Genetic Analysis and Cascade testing in Years past’.
93
Please join us for our monthly webinar on Wed 17th December at 3 pm UK time. This month's topic is a session on 'New Entities Identified Through Referral Practice' with Prof Glenn McCluggage. Free to register @ thebagp.org/events/list/ #PathTwitter #GynPath #Gynaepath
6
11
1,311
Prof Ranjit Manchanda retweeted
Women's Precision Prevention@wpp_wiph6 Oct 2025
Replying to @ProfManchanda
@ProfManchanda speaks at the 9th European Tumour Hereditary Group meeting held in Heidelberg in September. He had a keynote presentation on population screening strategies and implications of the PROTECTOR study and presented abstracts of findings from our PRESCORES study.
2
4
98
mdpi-res.com/d_attachment/ca… Great to see our paper out on PPOSSUM score for predicting morbidity in Ovarian cancer cytoreductive surgery. We show it is a poor predictor and should not be used.
1
3
2
130
New validated and accurate model(s) are necessary for predicting surgical morbidity in women undergoing cytoreductive ovarian cancer surgery. @QMUL_WIPH @QMUL_WIPH_CPDD @BGCS_org @BAGPGynPath @ESGO_society @Ovacome @TargetOvarian @OvarianCancerUK @eveappeal @wpp_wiph
1
73
Load more